`

ImpriMed, Inc

Biotechnology Research

Specialities :
Precision medicine
Veterinary medicine
Artificial intelligence
Biotechnology
Animal health

+2

revenue-icon Revenue
11M - 100M
funding-icon Total Funding
$23.0M
size-icon Size
11 - 50

Frequently Asked Questions About ImpriMed, Inc

What does Imprimed, inc do?+

ImpriMed, founded in 2017 in Silicon Valley, is a leading precision medicine startup revolutionizing cancer treatment with artificial intelligence. The companys pioneering drug response prediction technology helps reduce costs, accelerate treatment, enhance efficacy, and improve the quality of life for patients. To date, the companys technology has been deployed across more than 40 U.S. states, and 17,000+ canine and feline blood cancer tests have been performed as of 2024. ImpriMed is now poised to extend its groundbreaking AI-driven approach to human healthcare, redefining the future of oncology treatment with personalized, effective solutions. For additional information, visit www.imprimedicine.com

What are Imprimed, inc's specialties? +

Precision medicine,veterinary medicine,artificial intelligence,biotechnology,animal health,machine learning,and canine lymphoma

What is Imprimed, inc's industry? +

Imprimed, inc operates in the Biotechnology research industry.

What is Imprimed, inc's revenue? +

Imprimed, inc's revenue is 11m - 100m

What is Imprimed, inc's company size? +

Imprimed, inc has 11 - 50 employees.

The Go-to Sales Technology According to G2

G2 Badges Map
Get Started With Clodura
Sign Up

Sign Up for Free

Get Started with the Free Forever plan! No credit card needed. Enjoy up to 10,000 free email credits per month at no cost.

Supercharge Your Prospecting

Supercharge Your Prospecting

Start Prospecting from Clodura.AI's database of 600M+ verified B2B contacts and 120M+ direct dials along with 18M+ companies' org charts.

Grow Your Business

Grow Your Business

Unlock the prospect's contact details, including verified email, direct dials, add them to cadence, and close more deals.